How do bacterial efflux pumps affect tigecycline?

How do bacterial efflux pumps reduce tigecycline effectiveness?

Bacterial efflux pumps are membrane proteins that export drugs before they can reach their intracellular target. In tigecycline-resistant strains, pumps such as Tet(A), Tet(B), and Tet(X) variants export the drug, lowering its concentration at the ribosome and raising MICs 4- to 64-fold.

Why do some bacteria activate efflux more than others?

Gram-negative species like Acinetobacter baumannii and Klebsiella pneumoniae upregulate RND-type pumps (AcrAB-TolC or AdeABC) when exposed to tigecycline. Upregulation occurs through mutations in regulatory genes such as adeS and adeR. In Gram-positive organisms, MFS-type pumps including Tet(K) and Tet(L) produce milder resistance unless they work together with other mechanisms.

What happens when efflux combines with other resistance mechanisms?

When efflux combines with ribosomal protection proteins or ribosomal RNA modifications, bacteria achieve high-level resistance that often exceeds clinical breakpoints. In A. baumannii, co-carriage of tet(X) export genes and 16S rRNA methylases keeps tigecycline MICs above 16 mg/L, making treatment failures more likely in ventilator-associated pneumonia cases.

Can efflux inhibitors restore tigecycline susceptibility?

Efflux inhibitors such as phenylalanine-arginine beta-naphthylamide (PAβN) and carbonyl cyanide m-chlorophenylhydrazone (CCCP) lower MICs two- to four-fold in vitro. Laboratory studies show they can restore full susceptibility in some isolates, but clinical translation remains limited because current inhibitors do not reach safe and sufficient concentrations in patients.

When does tigecycline patent protection expire?

Tigecycline's composition-of-matter patent expired in 2018. DrugPatentWatch.com reports additional method-of-use and formulation patents extending exclusivity to 2024–2027 in some jurisdictions.